| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Nav1.3 505 nM (IC50); Nav1.7 181 nM (IC50); Nav1.8 397 nM (IC50)
The primary targets of 3'-Methoxydaidzein include voltage-gated sodium channels (NaV1.7, NaV1.8, and NaV1.3). It inhibits NaV1.7 with an IC50 of 181 nM, NaV1.8 with an IC50 of 397 nM, and NaV1.3 with an IC50 of 505 nM. By inhibiting these sodium channels, 3'-Methoxydaidzein may modulate pain signaling and neuronal excitability. The compound also exhibits antiplatelet aggregation activity, appearing to be specific against collagen-induced platelet aggregation with IC50 values of 12.3 and 61.5 µM. Its estrogenic activity classifies it as a phytoestrogen. |
|---|---|
| ln Vitro |
3'-Methoxydaidzein has been reported in Maackia amurensis, Dalbergia louvelii, and other organisms. 7,4'-dihydroxy-3'-methoxyisoflavone is a member of the class of 7-hydroxyisoflavones that is 7,4'-dihydroxyisoflavone substituted by a methoxy group at position 3'. It is isolated from the heart woods of Maackia amurensis subsp buergeri and Dalbergia louveli and exhibits antiplasmodial ativity. It has a role as a metabolite and an antiplasmodial drug. It is a methoxyisoflavone and a member of 7-hydroxyisoflavones.
In vitro, 3'-Methoxydaidzein inhibits sodium channel subtypes NaV1.7, NaV1.8, and NaV1.3 with IC50 values of 181 nM, 397 nM, and 505 nM, respectively. The compound also exhibits antiplatelet aggregation activity, with IC50 values of 12.3 and 61.5 µM against collagen-induced platelet aggregation. It has antioxidant, anti-inflammatory, and anticancer properties. 3'-Methoxydaidzein is a natural isoflavone with a molecular weight of 284.26 g/mol and is a phytoestrogen. |
| ln Vivo |
Isoflavones are widely consumed by people around the world in the form of soy products, dietary supplements and drugs. Many isoflavones or related crude extracts have been reported to exert pain-relief activities, but the mechanism remains unclear. Voltage-gated sodium channels (VGSCs) play important roles in excitability of pain sensing neurons and many of them are important nociceptors. Here, we report that several isoflavones including 3'-methoxydaidzein (3MOD), genistein (GEN) and daidzein (DAI) show abilities to block VGSCs and thus to attenuate chemicals and heat induced acute pain or chronic constriction injury (CCI) induced pain hypersensitivity in mice. Especially, 3MOD shows strong analgesic potential without inducing addiction through inhibiting subtypes NaV1.7, NaV1.8 and NaV1.3 with the IC50 of 181 ± 14, 397 ± 26, and 505 ± 46 nmol·L-1, respectively, providing a promising compound or parent structure for the treatment of pain pathologies. This study reveals a pain-alleviating mechanism of dietary isoflavones and may provide a convenient avenue to alleviate pain.[1]
In vivo, 3'-Methoxydaidzein has potential therapeutic applications due to its antioxidant, anti-inflammatory, anticancer, and antiplatelet activities. As a phytoestrogen, it may have effects on hormone-related conditions. Its inhibition of sodium channels suggests potential applications in pain research. However, detailed in vivo efficacy and safety data are not extensively reported in the available literature, and its use is primarily limited to preclinical research settings. Further studies are needed to fully characterize its in vivo effects and therapeutic potential. |
| Enzyme Assay |
In vitro assays for 3'-Methoxydaidzein typically involve measuring its inhibition of sodium channel activity using electrophysiological techniques such as patch-clamp recording in cell lines expressing recombinant NaV1.7, NaV1.8, or NaV1.3 channels. The compound is applied to the cells at varying concentrations (typically 1-1000 nM), and the resulting inhibition of sodium current is measured. The IC50 values of 181 nM, 397 nM, and 505 nM for NaV1.7, NaV1.8, and NaV1.3, respectively, are determined by fitting concentration-response curves. Antiplatelet aggregation activity is assessed using platelet aggregation assays with collagen as the inducer.
|
| Cell Assay |
Cellular assays for 3'-Methoxydaidzein typically use cell lines expressing recombinant sodium channels, such as HEK293 or CHO cells, for electrophysiological studies. The compound is applied to the cells, and its effects on channel activity are assessed using patch-clamp recording. Fluorescent-based membrane potential assays using voltage-sensitive dyes can also be used for higher-throughput screening of channel activity. Antiplatelet assays are performed using platelet-rich plasma, where the compound's ability to inhibit collagen-induced platelet aggregation is measured.
|
| Animal Protocol |
In vivo animal studies for 3'-Methoxydaidzein would likely involve the administration of the compound to rodent models to study its effects on pain, inflammation, cancer, or platelet aggregation. The compound could be administered via oral gavage or intraperitoneal injection. Endpoints would depend on the specific research question and could include pain-related behaviors, tumor growth, inflammatory markers, or platelet function. However, specific in vivo study protocols for 3'-Methoxydaidzein are not detailed in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 3'-Methoxydaidzein are not extensively reported in the available literature. The compound has a molecular weight of 284.26 g/mol and is a natural isoflavone. As a phytoestrogen, its pharmacokinetic properties would be expected to be similar to other isoflavones, with good oral bioavailability and metabolism by gut microbiota and hepatic enzymes. Detailed parameters such as half-life, volume of distribution, and bioavailability are not publicly available and would need to be determined experimentally.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for 3'-Methoxydaidzein in the available literature. As a natural product and research chemical, it is generally considered safe at research doses. However, standard safety precautions should be followed when handling the compound. Toxicity studies, including acute and sub-chronic dosing in animal models, would be required if the compound were to be developed further for therapeutic applications. The compound is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
7,4'-Dihydroxy-3'-methoxyisoflavone belongs to the 7-hydroxyisoflavone class of compounds and is formed by substituting a methoxy group at the 3' position of 7,4'-dihydroxyisoflavone. It was isolated from the heartwood of Maackia amurensis subsp. buergeri and Dalbergia louveli and possesses antimalarial activity. It is both a metabolite and an antimalarial drug. It is a methoxyisoflavone belonging to the 7-hydroxyisoflavone class of compounds. 3'-Methoxydaidzein has been reported in Maackia amurensis, Dalbergia louveli, and other organisms with relevant data.
3'-Methoxydaidzein is a natural isoflavone found in soybeans, red clover, and kudzu. It has a molecular formula of C16H12O5 and a molecular weight of 284.26 g/mol. The compound is a sodium channel inhibitor, inhibiting NaV1.7 (IC50=181 nM), NaV1.8 (IC50=397 nM), and NaV1.3 (IC50=505 nM). It also has antiplatelet aggregation activity and exhibits antioxidant, anti-inflammatory, and anticancer properties. 3'-Methoxydaidzein is a phytoestrogen. |
| Molecular Formula |
C16H12O5
|
|---|---|
| Molecular Weight |
284.26
|
| Exact Mass |
284.068
|
| CAS # |
21913-98-4
|
| PubChem CID |
5319422
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
534.5±50.0 °C at 760 mmHg
|
| Melting Point |
258-260℃
|
| Flash Point |
204.8±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.669
|
| LogP |
2.54
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)C2=COC3=C(C2=O)C=CC(=C3)O)O
|
| InChi Key |
MUYAUELJBWQNDH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O5/c1-20-15-6-9(2-5-13(15)18)12-8-21-14-7-10(17)3-4-11(14)16(12)19/h2-8,17-18H,1H3
|
| Chemical Name |
7-hydroxy-3-(4-hydroxy-3-methoxyphenyl)chromen-4-one
|
| Synonyms |
3'-Methoxydaidzein; 21913-98-4; 7,4'-dihydroxy-3'-methoxyisoflavone; 7-hydroxy-3-(4-hydroxy-3-methoxyphenyl)chromen-4-one; 4',7-dihydroxy-3'-methoxyisoflavone; CHEBI:65780; 7-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 7-Hydroxy-3-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 3'-Methoxydaidzein; 7,4'-Dihydroxy-3'-methoxyisoflavone;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5179 mL | 17.5895 mL | 35.1791 mL | |
| 5 mM | 0.7036 mL | 3.5179 mL | 7.0358 mL | |
| 10 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
